OralTopicalDosed ingredientTherapeutic flag
Cosmetic cross-reference
Tretinoin
CAS 302-79-4
Tretinoin (CAS 302-79-4) is a Phase 4 pharmaceutical compound with 22 bioactivity targets and 2,774 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
38
SOURCE
DrugCentral
Adverse signals
2,774
SOURCE
IUPHAR/BPS
PubMed IDs
10
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Tretinoin
CAS Number
302-79-4
UNII
5688UTC01R
InChIKey
SHGAZHPCJJPHSC-YCNIQYBTSA-N
ChEMBL ID
CHEMBL38
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Tri-LumaAmnesteemSotretClaravis
black box warningdosed ingredientnatural productoraltherapeutic flagtopical
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL38 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
38 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 28777.066172413794 nM | 289 | - |
| - | EC50 | 891.8449074074074 nM | 107 | - |
| - | GI50 | 51292.96511904762 nM | 84 | - |
| - | Potency | 25005.094680851063 nM | 69 | - |
| - | Kd | 140.89655172413794 nM | 58 | - |
| - | AC50 | 23986.510256410256 nM | 39 | - |
| - | Ki | 1114.2910344827585 nM | 29 | - |
| - | Kd | 15.333333333333334 | 3 | - |
| - | IC50 | 482 molar ratio | 1 | - |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 6.642 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 5.525 | - | Homo sapiens |
| Retinoic acid receptor alpha Nuclear hormone receptor |
EC50 | 6.7 | - | Homo sapiens |
| 11-cis retinol dehydrogenase Enzyme |
Ki | 7 | - | Homo sapiens |
| Nuclear receptor ROR-alpha Nuclear hormone receptor |
IC50 | 6.7 | - | Homo sapiens |
| Retinoic acid receptor RXR-alpha Nuclear hormone receptor |
Ki | 9.4 | - | Homo sapiens |
| Retinoic acid receptor RXR-beta Nuclear hormone receptor |
Ki | 9.3 | - | Homo sapiens |
| Retinoic acid receptor RXR-gamma Nuclear hormone receptor |
Ki | 8.85 | - | Homo sapiens |
| Retinoic acid receptor beta Nuclear hormone receptor |
EC50 | 6.7 | - | Homo sapiens |
| Retinoic acid receptor gamma Nuclear hormone receptor |
EC50 | 6.7 | - | Homo sapiens |
| Peroxisome proliferator-activated receptor delta Nuclear hormone receptor |
Kd | 7.8 | - | Homo sapiens |
| Nuclear receptor ROR-beta Nuclear hormone receptor |
IC50 | 9.82 | - | Homo sapiens |
| Nuclear receptor ROR-gamma Nuclear hormone receptor |
IC50 | 6.7 | - | Homo sapiens |
| Mitogen-activated protein kinase 1 Kinase |
IC50 | 6.24 | - | Homo sapiens |
| Cellular retinoic acid-binding protein 1 Cytosolic other |
IC50 | 6.43 | - | Gallus gallus |
| Retinoic acid receptor RXR-beta Transcription factor |
Kd | 6.51 | - | Mus musculus |
| Retinoic acid receptor RXR-gamma Transcription factor |
Kd | 6.46 | - | Mus musculus |
| Cellular retinoic acid-binding protein 1 Cytosolic other |
Kd | 9.4 | - | Mus musculus |
| Cellular retinoic acid-binding protein 2 Cytosolic other |
Kd | 8.7 | - | Mus musculus |
| Retinoic acid receptor alpha Transcription factor |
Kd | 7.82 | - | Mus musculus |
| Retinoic acid receptor RXR-alpha Transcription factor |
Kd | 6 | - | Mus musculus |
| Retinoic acid receptor beta Transcription factor |
Kd | 7.89 | - | Mus musculus |
| Retinoic acid receptor gamma Transcription factor |
Kd | 7.74 | - | Mus musculus |
| Indoleamine 2,3-dioxygenase 2 Enzyme |
IC50 | 4.54 | - | Mus musculus |
| Nuclear receptor subfamily 2 group E member 1 Nuclear hormone receptor |
EC50 | 5.74 | - | Homo sapiens |
| Amyloid beta A4 protein Unclassified |
IC50 | 6.75 | - | Homo sapiens |
| Nuclear receptor subfamily 2 group C member 2 Nuclear other |
EC50 | 4.62 | - | Homo sapiens |
| Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Unclassified |
IC50 | 6.09 | - | Homo sapiens |
| Alpha-synuclein Transporter |
IC50 | 5.52 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Differentiation syndrome | 401 | 2387.763 | 10080638 |
| Idiopathic intracranial hypertension | 98 | 415.966 | 10078904 |
| Blepharospasm | 82 | 279.346 | 10005159 |
| Leukaemia recurrent | 65 | 254.275 | 10062489 |
| Taste disorder | 82 | 197.672 | 10082490 |
| Product use in unapproved indication | 227 | 192.222 | 10076476 |
| Hyperleukocytosis | 47 | 179.561 | 10078862 |
| Myelodysplastic syndrome transformation | 32 | 138.498 | 10067387 |
| Epilepsy | 83 | 134.708 | 10015037 |
| Haematopoietic neoplasm | 19 | 118.25 | 10061187 |
| Acute myeloid leukaemia | 67 | 110.559 | 10000880 |
| Intracranial pressure increased | 41 | 102.915 | 10022773 |
| Myelodysplastic syndrome | 60 | 92.661 | 10028533 |
| Migraine | 96 | 91.213 | 10027599 |
| Electrocardiogram QT prolonged | 87 | 87.909 | 10014387 |
| Gastrooesophageal reflux disease | 92 | 76.13 | 10017885 |
| Memory impairment | 92 | 71.225 | 10027175 |
| Hypoaesthesia | 116 | 69.884 | 10020937 |
| Haemorrhage intracranial | 45 | 65.668 | 10018985 |
| Paraesthesia | 108 | 62.546 | 10033775 |
| Haemorrhage | 74 | 55.14 | 10055798 |
| Febrile neutropenia | 114 | 54.724 | 10016288 |
| Cytogenetic abnormality | 17 | 54.098 | 10067477 |
| Pulmonary haemorrhage | 32 | 52.086 | 10037394 |
| Scrotal ulcer | 12 | 51.335 | 10039760 |
| Congenital knee dislocation | 9 | 50.204 | 10010520 |
| Neutropenia | 129 | 48.103 | 10029354 |
| Abortion spontaneous | 43 | 46.255 | 10000234 |
| Dry skin | 57 | 45.758 | 10013786 |
| Papilloedema | 21 | 45.433 | 10033712 |
| Second primary malignancy | 29 | 44.654 | 10039801 |
| Abdominal pain upper | 108 | 43.56 | 10000087 |
| Disseminated intravascular coagulation | 38 | 41.495 | 10013442 |
| Hypercalcaemia | 39 | 40.148 | 10020583 |
| Myocarditis | 29 | 37.877 | 10028606 |
| Thrombocytopenia | 111 | 37.272 | 10043554 |
| Acute promyelocytic leukaemia | 12 | 36.739 | 10001019 |
| Off label use | 280 | 34.51 | 10053762 |
| Large granular lymphocytosis | 8 | 30.692 | 10023791 |
| Acute febrile neutrophilic dermatosis | 14 | 30.682 | 10000748 |
| Dysphoria | 16 | 29.191 | 10013954 |
| Mucosal inflammation | 47 | 28.529 | 10028116 |
| Polyarteritis nodosa | 8 | 27.745 | 10036024 |
| VIth nerve paralysis | 10 | 26.859 | 10047641 |
| Haemorrhagic diathesis | 15 | 26.651 | 10062713 |
| Skin warm | 15 | 26.191 | 10040952 |
| IIIrd nerve paralysis | 9 | 26.099 | 10021283 |
| Chloroma | 8 | 25.641 | 10008583 |
| Hepatotoxicity | 37 | 25.564 | 10019851 |
| Contraindicated product administered | 3 | 25.267 | 10078504 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
12 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Retinoic acid receptor-α RARA |
Agonist | 9.399999618530273 pKd | 8380496|8264595|10964567|7791761|10637371 |
| Retinoic acid receptor-α RARA |
Agonist | 7.769999980926514 pEC50 | 19058965 |
| Retinoic acid receptor-β RARB |
Agonist | 9.399999618530273 pKi | 8264595|10964567|7791761|10637371 |
| Retinoic acid receptor-β RARB |
Agonist | 7.920000076293945 pEC50 | 19058965 |
| Retinoic acid receptor-γ RARG |
Agonist | 9.600000381469727 pKd | 8380496|8264595|10964567|7791761|10637371 |
| Retinoic acid receptor-γ RARG |
Agonist | 9.699999809265137 pEC50 | 19058965 |
| Peroxisome proliferator-activated receptor-β/δ PPARD |
Full agonist | 7.800000190734863 pKd | 12963727 |
| RAR-related orphan receptor-β RORB |
Agonist | - | 12958591 |
| RAR-related orphan receptor-β RORB |
Antagonist | 9.82 pIC50 | 12958591 |
| RAR-related orphan receptor-β RORB |
Antagonist | 6.55 pKi | 12958591 |
| TLX NR2E1 |
Agonist | 5.739999771118164 pEC50 | 32763139 |
| Testicular receptor 4 NR2C2 |
Full agonist | 4.619999885559082 pEC50 | 21068381 |
SOURCE
NLM RxNorm
8 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Tretinoin | 10753 | SU | MTHSPL |
| tretinoin | 10753 | SU | MTHSPL |
| TRETINOIN | 10753 | SU | MTHSPL |
| tretinoin | 10753 | IN | RXNORM |
| Tri-Luma | 353031 | BN | RXNORM |
| Amnesteem | 404854 | BN | RXNORM |
| Sotret | 405330 | BN | RXNORM |
| Claravis | 405944 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | retinoic | PT | C0232487 |
| Abdominal distension | retinoic | LLT | C0000731 |
| Abdominal distension | retinoic | PT | C0000731 |
| Abdominal pain | retinoic | LLT | C0000737 |
| Abdominal pain | retinoic | PT | C0000737 |
| Acidosis | retinoic | LLT | C0001122 |
| Acidosis | retinoic | PT | C0001122 |
| Acne | retinoic | LLT | C0702166 |
| Acne | retinoic | PT | C0702166 |
| Acneiform eruption | retinoic | LLT | C0175167 |
| Acute coronary syndrome | retinoic | PT | C0948089 |
| Acute febrile neutrophilic dermatosis | retinoic | LLT | C0085077 |
| Acute febrile neutrophilic dermatosis | retinoic | PT | C0085077 |
| Agitation | retinoic | LLT | C0085631 |
| Agitation | retinoic | PT | C0085631 |
| Agnosia | retinoic | LLT | C0001816 |
| Agnosia | retinoic | PT | C0001816 |
| Allergic contact dermatitis | retinoic | LLT | C0162820 |
| Alopecia | retinoic | LLT | C0002170 |
| Alopecia | retinoic | PT | C0002170 |
| Anorexia | retinoic | LLT | C0003123 |
| Anxiety | retinoic | LLT | C0003467 |
| Anxiety | retinoic | PT | C0003467 |
| Aphasia | retinoic | LLT | C0003537 |
| Aphasia | retinoic | PT | C0003537 |
| Application site erythema | retinoic | LLT | C0853700 |
| Application site erythema | retinoic | PT | C0853700 |
| Application site oedema | retinoic | LLT | C0234936 |
| Application site oedema | retinoic | PT | C0234936 |
| Application site pain | retinoic | PT | C0521491 |
| Application site pruritus | retinoic | LLT | C0853714 |
| Application site pruritus | retinoic | PT | C0853714 |
| Application site rash | retinoic | LLT | C0521495 |
| Application site rash | retinoic | PT | C0521495 |
| Application site stinging | retinoic | LLT | C2721737 |
| Arrhythmia | retinoic | LLT | C0003811 |
| Arrhythmia | retinoic | PT | C0003811 |
| Arthralgia | retinoic | LLT | C0003862 |
| Arthralgia | retinoic | PT | C0003862 |
| Ascites | retinoic | LLT | C0003962 |
| Ascites | retinoic | PT | C0003962 |
| Asterixis | retinoic | LLT | C0232766 |
| Asterixis | retinoic | PT | C0232766 |
| Asthenia | retinoic | LLT | C0004093 |
| Asthenia | retinoic | PT | C0004093 |
| Asthenia | retinoic | PT | C0004093 |
| Asthma | retinoic | LLT | C0004096 |
| Asthma | retinoic | PT | C0004096 |
| Auditory disorder NOS | retinoic | LLT | C0260662 |
| Back pain | retinoic | LLT | C0004604 |
| Back pain | retinoic | PT | C0004604 |
| Basophilia | retinoic | LLT | C0702266 |
| Basophilia | retinoic | PT | C0702266 |
| Benign intracranial hypertension | retinoic | LLT | C0033845 |
| Benign intracranial hypertension | retinoic | PT | C0033845 |
| Bladder pain | retinoic | PT | C0232849 |
| Blindness | retinoic | PT | C0456909 |
| Blister | retinoic | LLT | C0005758 |
| Blister | retinoic | PT | C0005758 |
| Blood bilirubin increased | retinoic | LLT | C0311468 |
| Blood bilirubin increased | retinoic | PT | C0311468 |
| Blood creatinine increased | retinoic | PT | C0235431 |
| Blood triglycerides increased | retinoic | PT | C0853692 |
| Body temperature decreased | retinoic | LLT | C0020672 |
| Body temperature decreased | retinoic | PT | C0020672 |
| Body temperature increased | retinoic | LLT | C0015967 |
| Body temperature increased | retinoic | PT | C0015967 |
| Bone pain | retinoic | LLT | C0151825 |
| Bone pain | retinoic | PT | C0151825 |
| Brain oedema | retinoic | PT | C1527311 |
| Buccal mucosa ulceration | retinoic | LLT | C0235344 |
| CNS depression NOS | retinoic | LLT | C0151559 |
| Candida infection | retinoic | LLT | C0006840 |
| Candida infection | retinoic | PT | C0006840 |
| Cardiac arrest | retinoic | LLT | C0018790 |
| Cardiac arrest | retinoic | PT | C0018790 |
| Cardiac failure | retinoic | LLT | C0018801 |
| Cardiac failure | retinoic | PT | C0018801 |
| Cardiac failure congestive | retinoic | LLT | C0018802 |
| Cardiac failure congestive | retinoic | PT | C0018802 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tretinoin used for in pharmaceutical contexts?
Tretinoin (CAS 302-79-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tretinoin?
Tretinoin has 2,774 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Differentiation syndrome, Idiopathic intracranial hypertension, Blepharospasm, Leukaemia recurrent, Taste disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tretinoin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Tretinoin with EU status "prohibited".
What clinical phase is Tretinoin in?
Tretinoin is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Tretinoin?
Tretinoin has 38 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 2B, Adenosine receptor A3, Retinoic acid receptor alpha, 11-cis retinol dehydrogenase, Nuclear receptor ROR-alpha.